Physician profile
Janna Van Mudd
NPI 1568598910
$616.90
in general payments reported to CMS, 2019-2025
14 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.75 · 2021: $99.64 · 2022: $123 · 2023: $128 · 2024: $134 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $107.12 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $102.02 | 2022-2025 | |
| Exeltis, USA INC. | $97.72 | 2021-2025 | Slynd |
| Scynexis, INC. | $59.97 | 2022 | |
| Evofem Biosciences, INC. | $45.72 | 2025 | Solosec, Phexx, Phexxi |
| Abbvie INC. | $42.55 | 2021 | |
| Mylan Pharmaceuticals INC. | $40.03 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.75 | 2021-2023 | |
| Hologic Sales and Service, LLC | $23.72 | 2025 | Aptima |
| Therapeuticsmd, INC. | $18.75 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $13.46 | 2024 | |
| Ethicon US, LLC | $13.25 | 2023 | Surgiflo Hemostatic Matrix, Stratafix, Vistaseal |
| Meditrina | $11.68 | 2024 | |
| Novo Nordisk INC | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janna Mudd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.